The iron chelator deferasirox protects mice from mucormycosis through iron starvation
Open accessThe DOI matches its Crossref record; 43 of the 43 references it cites were found in a registry or an index.
Abstract
Mucormycosis causes mortality in at least 50% of cases despite current first-line therapies. Clinical and animal data indicate that the presence of elevated available serum iron predisposes the host to mucormycosis. Here we demonstrate that deferasirox, an iron chelator recently approved for use in humans by the US FDA, is a highly effective treatment for mucormycosis. Deferasirox effectively chelated iron from Rhizopus oryzae and demonstrated cidal activity in vitro against 28 of 29 clinical isolates of Mucorales at concentrations well below clinically achievable serum levels. When administered to diabetic ketoacidotic or neutropenic mice with mucormycosis, deferasirox significantly improved survival and decreased tissue fungal burden, with an efficacy similar to that of liposomal amphotericin B. Deferasirox treatment also enhanced the host inflammatory response to mucormycosis. Most importantly, deferasirox synergistically improved survival and reduced tissue fungal burden when combined with liposomal amphotericin B. These data support clinical investigation of adjunctive deferasirox therapy to improve the poor outcomes of mucormycosis with current therapy. As iron availability is integral to the pathogenesis of other infections (e.g., tuberculosis, malaria), broader investigation of deferasirox as an antiinfective treatment is warranted.
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Claims other papers make about this one
Each is checked against this paper’s own text: does it say what the citing paper says it does?
The source backs part of the claim, not all of it — or backs it for a different population, condition or comparison.
In the citing paper
“This pathway appears to be partly responsible for the beneficial clinical effects of iron chelators observed in several experimental infection systems (Mencacci et al., 1997; Fritsche et al., 2001; Ibrahim et al., 2007; Bellmann-Weiler et al., 2013; Nairz et al., 2013).”
From Iron at the interface of immunity and infection (2014) · cites this paper as Ibrahim et al., 2007
Experimental — accuracy not yet measuredThe cited source says what the claim attributes to it.
In the citing paper
“However, the Fe chelator desferasirox, which cannot be used by molds to acquire Fe, improves survival of infected mice, limiting Fe availability to the pathogen while enhancing host resistance mechanisms [238].”
From The Iron age of host–microbe interactions (2015) · cites this paper as [238]
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
Epidemiology and Outcome of Zygomycosis: A Review of 929 Reported Cases
Roden, M. M., Zaoutis, T. E., Buchanan, W. L., Knudsen, T. A., Sarkisova, T. A., Schaufele, R. L., Sein, M., Sein, T., Chiou, C. C., Chu, J. H., et al. (2005) · Clinical Infectious Diseases · doi:10.1086/432579 · Cited by 3,044
Hentze, M. W., Muckenthaler, M. U., & Andrews, N. C. (2004) · Cell · doi:10.1016/s0092-8674(04)00343-5 · Cited by 1,736
Ribes, J. A., Vanover-Sams, C. L., & Baker, D. J. (2000) · Clinical Microbiology Reviews · doi:10.1128/cmr.13.2.236 · Cited by 1,711
Novel perspectives on mucormycosis: pathophysiology, presentation, and management
Spellberg, B., Edwards, J., & Ibrahim, A. (2005) · Clinical Microbiology Reviews · doi:10.1128/cmr.18.3.556-569.2005 · Cited by 1,537
Self-citationEpidemiology and Outcome of Mould Infections in Hematopoietic Stem Cell Transplant Recipients
Marr, K. A., Carter, R. A., Crippa, F., Wald, A., & Corey, L. (2002) · Clinical Infectious Diseases · doi:10.1086/339202 · Cited by 1,448
Schaible, U. E., & Kaufmann, S. H. E. (2004) · Nature Reviews Microbiology · doi:10.1038/nrmicro1046 · Cited by 945
Cappellini, M. D. (2006) · Blood · doi:10.1182/blood-2005-08-3430 · Cited by 717 · cited 2×
“Furthermore, it is known that deferasirox chelation is specific for iron and that other trace metals and cations are not affected by the drug (27, 28).”
Zygomycosis in the 1990s in a Tertiary-Care Cancer Center
Kontoyiannis, D. P., Wessel, V. C., Bodey, G. P., & Rolston, K. V. I. (2000) · Clinical Infectious Diseases · doi:10.1086/313803 · Cited by 521
Artis, W. M., Fountain, J. A., Delcher, H. K., & Jones, H. E. (1982) · Diabetes · doi:10.2337/diabetes.31.12.1109 · Cited by 369 · cited 2×
“Alternatively, the enhanced efficacy of deferasirox in the diabetic ketoacidotic mouse model might reflect the ability of this iron chelator to efficiently chelate serum iron previously freed by proton-mediated dissociation from iron-sequestering proteins (2, 16, 17).”
Boelaert, J. R., de Locht, M., Van Cutsem, J., Kerrels, V, Cantinieaux, B., Verdonck, A., Van Landuyt, H. W., & Schneider, Y. J. (1993) · Journal of Clinical Investigation · doi:10.1172/jci116419 · Cited by 340 · cited 2×
“The potential therapeutic role of iron chelation therapy for mucormycosis was initially obscured by the paradoxically increased risk of developing mucormycosis during treatment with deferox-amine (18).”
Husain, S., Alexander, B. D., Munoz, P., Avery, R. K., Houston, S., Pruett, T., Jacobs, R., Dominguez, E. A., Tollemar, J. G., Baumgarten, K., et al. (2003) · Clinical Infectious Diseases · doi:10.1086/375822 · Cited by 337
Nisbet-Brown, E., Olivieri, N. F., Giardina, P. J., Grady, R. W., Neufeld, E. J., Séchaud, R., Krebs-Brown, A. J., Anderson, J. R., Alberti, D., Sizer, K. C., et al. (2003) · The Lancet · doi:10.1016/s0140-6736(03)13309-0 · Cited by 328 · cited 2×
“Furthermore, the MICs and MFCs of deferasirox against these isolates were well below clinically achievable peak ( ~ 38 μ g/ml) and trough serum levels ( ~ 17 μ g/ml) of the drug at steady state when administered at the FDA-approved starting dose (20 mg/kg/d) (25).”
How pathogenic bacteria evade mammalian sabotage in the battle for iron
Fischbach, M. A., Lin, H., Liu, D. R., & Walsh, C. T. (2006) · Nature Chemical Biology · doi:10.1038/nchembio771 · Cited by 321 · cited 2×
“The role of iron sequestration in innate host defense against infection has gained increasing attention of late (8–11, 23, 24).”
Espinel-Ingroff, A. (2001) · Journal of Clinical Microbiology · doi:10.1128/jcm.39.3.954-958.2001 · Cited by 296 · cited 6×
“The MIC 90 s (minimum concentrations at which 90% of isolates were inhibited) of deferasirox against Mucor spp, non-oryzae Rhizopus spp, and R. oryzae were 3.12–6.25 μ g/ml. Minimum fungicidal concentrations (MFCs) were similar to MICs, and deferasirox was cidal for 28 of 29 (97”
InfluentialOrchestration of Iron Homeostasis
Fleming, R. E., & Bacon, B. R. (2005) · New England Journal of Medicine · doi:10.1056/nejmp048363 · Cited by 258
Improved Outcome of Zygomycosis in Patients with Hematological Diseases?
Gleissner, B., Schilling, A., Anagnostopolous, I., Siehl, I., & Thiel, E. (2004) · Leukemia & Lymphoma · doi:10.1080/10428190310001653691 · Cited by 227
Waldorf, A. R., Ruderman, N., & Diamond, R. D. (1984) · Journal of Clinical Investigation · doi:10.1172/jci111395 · Cited by 215 · cited 1×
“For the intra-nasal infection, 10 7 spores in 20 μ l of 0.01% Tween-80 in PBS were placed on the nostrils of ketamine-sedated (100 mg/kg) mice (43).”
InfluentialIbrahim, A. S., Bowman, J. C., Avanessian, V., Brown, K., Spellberg, B., Edwards, J. E., & Douglas, C. M. (2005) · Antimicrobial Agents and Chemotherapy · doi:10.1128/aac.49.2.721-727.2005 · Cited by 207
Self-citationGalanello, R., Piga, A. G., Alberti, D., Rouan, M. C., Bigler, H., & Séchaud, R. (2003) · PubMed · Cited by 169
Iron Overload Alters Innate and T Helper Cell Responses to Candida albicans in Mice
Mencacci, A., Cenci, E., Boelaert, J. R., Bucci, P., Mosci, P., d'Ostiani, C. F., Bistoni, F., & Romani, L. (1997) · The Journal of Infectious Diseases · doi:10.1086/516481 · Cited by 169
Boelaert, J. R., Van Cutsem, J., de Locht, M., Schneider, Y.-J., & Crichton, R. R. (1994) · Kidney International · doi:10.1038/ki.1994.89 · Cited by 168 · cited 1×
“Specifically, treatment of Rhizopus -infected mice (16) or guinea pigs (13) with the iron chelator deferiprone markedly improved survival.”
Natural resistance, iron and infection: a challenge for clinical medicine
Bullen, J. J., Rogers, H. J., Spalding, P. B., & Ward, C. G. (2006) · Journal of Medical Microbiology · doi:10.1099/jmm.0.46386-0 · Cited by 163 · cited 1×
“Iron is required by virtually all microbial pathogens for growth and virulence (9, 10).”
Hepcidin—A Peptide Hormone at the Interface of Innate Immunity and Iron Metabolism
Ganz, T. (2006) · Springer eBooks · doi:10.1007/3-540-29916-5_7 · Cited by 162 · cited 4×
“Because of its unacceptably high mortality rate, and the morbidity of dis-figuring surgical therapy, it is desirable to develop new antifungal therapies to treat invasive mucormycosis (8).”
InfluentialEpidemiology of opportunistic invasive mycoses.
Kullberg, B. J., & Lashof, A. M. L. O. (2002) · PubMed · Cited by 159
Deferiprone iron chelation as a novel therapy for experimental mucormycosis
Ibrahim, A. S., Edwards, J. E., Fu, Y., & Spellberg, B. (2006) · Journal of Antimicrobial Chemotherapy · doi:10.1093/jac/dkl350 · Cited by 156 · cited 5×
“Alternatively, the enhanced efficacy of deferasirox in the diabetic ketoacidotic mouse model might reflect the ability of this iron chelator to efficiently chelate serum iron previously freed by proton-mediated dissociation from iron-sequestering proteins (2, 16, 17).”
InfluentialSelf-citationGalanello, R., Piga, A., Alberti, D., Rouan, M.-C., Bigler, H., & Séchaud, R. (2003) · Journal of Clinical Pharmacology · doi:10.1177/0091270003043006002 · Cited by 141
Taxonomic, R. (1980) · Cited by 138
Deferasirox, an Iron-Chelating Agent, as Salvage Therapy for Rhinocerebral Mucormycosis
Reed, C., Ibrahim, A., Edwards, J. E., Walot, I., & Spellberg, B. (2006) · Antimicrobial Agents and Chemotherapy · doi:10.1128/aac.01065-06 · Cited by 136
Self-citationMiceli, M. H., Dong, L., Grazziutti, M., Fassas, A., Thertulien, R., van Rhee, F., Barlogie, B., & Anaissie, E. J. (2006) · Bone Marrow Transplantation · doi:10.1038/sj.bmt.1705340 · Cited by 128 · cited 1×
“The role of iron sequestration in innate host defense against infection has gained increasing attention of late (8–11, 23, 24).”
de Locht, M., Boelaert, J. R., & Schneider, Y. (1994) · Biochemical Pharmacology · doi:10.1016/0006-2952(94)90314-x · Cited by 124
Effects of deferoxamine, feroxamine and iron on experimental mucormycosis (zygomycosis)
Cutsem, J. V., & Boelaert, J. R. (1989) · Kidney International · doi:10.1038/ki.1989.301 · Cited by 108
Thorson, J. A., Smith, K. M., Gomez, F., Naumann, P. W., & Kemp, J. D. (1991) · Cellular Immunology · doi:10.1016/0008-8749(91)90336-a · Cited by 98
Ibrahim, A. S., Avanessian, V., Spellberg, B., & Edwards, J. E. (2003) · Antimicrobial Agents and Chemotherapy · doi:10.1128/aac.47.10.3343-3344.2003 · Cited by 97 · cited 1×
“For in vivo infection, BALB/c male mice (≥20 g) were rendered diabetic with a single i.p. injection of 210 mg/kg streptozotocin in 0.2 ml citrate buffer 10 days prior to fungal challenge (41).”
InfluentialSelf-citationThe effects of iron deficiency and iron overload on cell-mediated immunity in the mouse
Omara, F. O., & Blakley, B. R. (1994) · British Journal of Nutrition · doi:10.1079/bjn19940094 · Cited by 89 · cited 1×
“Our findings are consistent with previous studies demonstrating that iron overload suppresses cell-mediated immune responses and inflammation, including production of canonical Th1 cytokines such as IFN-γ or IL-12 (29–31).”
Nick, H., Wong, A. M.-L., Acklin, P., Faller, B., Jin, Y., Lattmann, R., Sergejew, T., Hauffe, S., Thomas, H., & Schnebli, H. P. (2002) · Advances in experimental medicine and biology · doi:10.1007/978-1-4615-0593-8_10 · Cited by 72 · cited 2×
“Furthermore, it is known that deferasirox chelation is specific for iron and that other trace metals and cations are not affected by the drug (27, 28).”
Spellberg, B., Johnston, D., Phan, Q. T., Edwards, J. E., French, S. W., Ibrahim, A. S., & Filler, S. G. (2003) · Infection and Immunity · doi:10.1128/iai.71.10.5756-5764.2003 · Cited by 68 · cited 1×
“Splenic Th1 (CD4 + IFN-γ + IL-4 – ) and Th2 (CD4 + IFN-γ – IL-4 + ) lymphocyte frequencies were determined as we have previously described (44).”
Self-citationEffects of iron and desferrioxamine on Rhizopus infection
Abe, F., Inaba, H., Katoh, T., & Hotchi, M. (1990) · Mycopathologia · doi:10.1007/bf00446996 · Cited by 64 · cited 2×
“Furthermore, administration of deferoxamine worsens survival of animals with mucormycosis (12–15 ).”
FU, Y. (2004) · FEMS Microbiology Letters · doi:10.1016/j.femsle.2004.04.031 · Cited by 53
Self-citationHomologous recombination and double-strand break repair in the transformation of Rhizopus oryzae
Skory, C. D. (2002) · Molecular Genetics and Genomics · doi:10.1007/s00438-002-0760-8 · Cited by 45 · cited 2×
“Amplified fragments were ligated into the XbaI and EagI sites of plasmid pyr225b (38).”
Self-citationA phagocytic cell line markedly improves survival of infected neutropenic mice
Spellberg, B. J., Collins, M., French, S. W., Edwards, J. E., Fu, Y., & Ibrahim, A. S. (2005) · Journal of Leukocyte Biology · doi:10.1189/jlb.0205072 · Cited by 43 · cited 1×
“This treatment regimen resulted in pancytopenia from day –2 to day 5 relative to infection, with recovery of cell counts beginning on day 6 after infection (42).”
Self-citationIdentifying Modulators of hERG Channel Activity Using the PatchXpress® Planar Patch Clamp
Dubin, A. E., Nasser, N., Rohrbacher, J., Hermans, A. N., Marrannes, R., Grantham, C., Van Rossem, K., Cik, M., Chaplan, S. R., Gallacher, D., et al. (2005) · SLAS Discovery · doi:10.1177/1087057104272394 · Cited by 41
Plasmids for expression of heterologous proteins in Rhizopus oryzae
Mertens, J. A., Skory, C. D., & Ibrahim, A. S. (2006) · Archives of Microbiology · doi:10.1007/s00203-006-0121-9 · Cited by 36 · cited 1×
“31 (39) and cloned downstream of either promoter into EagI-SacI sites of the plasmid.”
Self-citationDesferrioxamine modulates chemically induced T helper 2-mediated autoimmunity in the rat
WU, Z., HOLWILL, S. D. J., & OLIVEIRA, D. B. G. (2004) · Clinical and Experimental Immunology · doi:10.1111/j.1365-2249.2003.02372.x · Cited by 25 · cited 1×
“Our findings are consistent with previous studies demonstrating that iron overload suppresses cell-mediated immune responses and inflammation, including production of canonical Th1 cytokines such as IFN-γ or IL-12 (29–31).”
Research works printed but not linked: 4
- Ganz, 2006, Curr. Top. Microbiol. Immunol., 306, 183
- Artis, 1982, Diabetes., 31, 1109, 10.2337/diacare.31.12.1109 · doi:10.2337/diacare.31.12.1109 · Paper page
- Fu, 2004, FEMS Microbiol. Lett., 235, 169
- Ibrahim, A.S., et al. 2000. Comparison of amphotericin B and amphotericin B lipid complex in the treatment of murine-induced zygomycosis. In 40th Interscience Conference on Antimicrobial Agents and Chemotherapy. September 17–20. Toronto, Ontario, Canada. American Society of Microbiology. Abstract 1681.
Cited by
ESCMID† and ECMM‡ joint clinical guidelines for the diagnosis and management of mucormycosis 2013
Cornely, O. A., Arikan-Akdagli, S., Dannaoui, E., Groll, A. H., Lagrou, K., Chakrabarti, A., Lanternier, F., Pagano, L., Skiada, A., Akova, M., et al. (2014) · Clinical Microbiology and Infection · doi:10.1111/1469-0691.12371 · Cited by 863
Ibrahim, A. S., Spellberg, B., Walsh, T. J., & Kontoyiannis, D. P. (2012) · Clinical Infectious Diseases · doi:10.1093/cid/cir865 · Cited by 824
“chelators, such as deferiprone and deferasirox [24, 25], which are not used by Mucorales as xenosiderophores.”
BackgroundSelf-citationGuidelines for the Management of Transfusion Dependent Thalassaemia (TDT)
Cappellini, M. D., Cohen, A. R., Porter, J. B., Taher, A. T., & Viprakasit, V. (2014) · Cited by 726
Challenges in the diagnosis and treatment of mucormycosis
Skiada, A., Lass-Floerl, C., Klimko, N., Ibrahim, A., Roilides, E., & Petrikkos, G. (2018) · Medical Mycology · doi:10.1093/mmy/myx101 · Cited by 568
Self-citationRecent Advances in the Management of Mucormycosis: From Bench to Bedside
Spellberg, B., Walsh, T. J., Kontoyiannis, D. P., Edwards, Jr., & Ibrahim, A. S. (2009) · Clinical Infectious Diseases · doi:10.1086/599105 · Cited by 548
“0% for placebo) [21].”
Self-citation
Metadata
- Authors
- Ibrahim, A. S., Gebermariam, T., Fu, Y., Lin, Husseiny, M. I., French, S. W., Schwartz, J., Skory, C. D., Edwards, J. E., & Spellberg, B. J.
- Affiliations
- University of California, Los Angeles (US)
- Charles River Laboratories (United States) (US)
- National Center for Agricultural Utilization Research (US)
- Corresponding author
- Ibrahim, Ashraf S.
- ORCID
- Venue
- Journal of Clinical Investigation
- Published
- 2007-09-04
- Volume
- 117
- Issue
- 9
- Pages
- 2649-2657
- ISSN
- 0021-9738 (ISSN-L)
- PMC
- PMC1957543
- OpenAlex
- W2113977119
- Cited by
- 308
- References
- 43
- Citations by year
- 2026: 6 · 2025: 5 · 2024: 13 · 2023: 16 · 2022: 17 · 2021: 21 · 2020: 15 · 2019: 12 · 2018: 12 · 2017: 12 · 2016: 12 · 2015: 15 · 2014: 20 · 2013: 23 · 2012: 25
- FWCI
- 13.63
- Type
- journal article
- Language
- en
- Open access
- green
- www.ncbi.nlm.nih.gov
- Locations
- Journal of Clinical Investigation (publishedVersion)
- PubMed Central (publishedVersion)
- PubMed (publishedVersion)
- Funders
- Bristol-Myers Squibb
- Gilead Sciences
- National Institute of Allergy and Infectious Diseases (R01 AI63503-01A2, R01AI019990, K08AI060641, AI-063382, R01-AI19990, R21AI064716, R01AI063382, R01AI063503)
- Topics
- Health Sciences › Medicine › Infectious Diseases › Antifungal resistance and susceptibility
- Health Sciences › Medicine › Infectious Diseases › Fungal Infections and Studies
- Life Sciences › Biochemistry, Genetics and Molecular Biology › Molecular Biology › Fungal and yeast genetics research
- Keywords
- mucormycosis, deferasirox, iron chelation, iron starvation, Mucorales, Rhizopus oryzae, liposomal amphotericin B, antifungal therapy, diabetic ketoacidosis, neutropenia, host inflammatory response, serum iron, adjunctive therapy
- MeSH terms
- Deferasirox, Amphotericin B, Animals, Benzoates, Diabetes Mellitus, Drug Therapy, Combination, Iron, Iron Chelating Agents, Liposomes, Male, Mice, Inbred BALB C, Mucorales, Mucormycosis, Triazoles, Survival Rate, Th1 Cells, Th2 Cells, Mice
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.